Multi-country oncology trial starts vs Oncology novel active substance (NAS) launches (cumulative)

In 2015, multi-country oncology trial starts worldwide stood at 503, against 79 for oncology novel active substance (NAS) launches (cumulative).

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.

Multi-country oncology trial starts and Oncology novel active substance (NAS) launches (cumulative)

Unit: count · 6 observations

2 series · one axis
Multi-country oncology trial starts and Oncology novel active substance (NAS) launches (cumulative): GlobalMulti-country oncology trial starts and Oncology novel active substance (NAS) launches (cumulative). 2 indicators on one axis: Multi-country oncology trial starts, Oncology novel active substance (NAS) launches (cumulative). 6 observations from 2005–2024 to 2024, ranging from 79 to 644. Latest values: Multi-country oncology trial starts 403 (2024); Oncology novel active substance (NAS) launches (cumulative) 132 (2020–2024). 0 200 400 600 800 2005 2008 2011 2014 2017 2020 2023 403 132 Multi-country oncology trial starts Oncology novel active substance (NAS) launches (cumulative)
Multi-country oncology trial starts and Oncology novel active substance (NAS) launches (cumulative): GlobalMulti-country oncology trial starts and Oncology novel active substance (NAS) launches (cumulative). 2 indicators on one axis: Multi-country oncology trial starts, Oncology novel active substance (NAS) launches (cumulative). 6 observations from 2005–2024 to 2024, ranging from 79 to 644. Latest values: Multi-country oncology trial starts 403 (2024); Oncology novel active substance (NAS) launches (cumulative) 132 (2020–2024). 0 200 400 600 800 2005 2008 2011 2014 2017 2020 2023 403 132 Multi-country oncology trial starts Oncology novel active substance (NAS) launches (cumulative)
Multi-country oncology trial starts and Oncology novel active substance (NAS) launches (cumulative): GlobalMulti-country oncology trial starts and Oncology novel active substance (NAS) launches (cumulative). 2 indicators on one axis: Multi-country oncology trial starts, Oncology novel active substance (NAS) launches (cumulative). 6 observations from 2005–2024 to 2024, ranging from 79 to 644. Latest values: Multi-country oncology trial starts 403 (2024); Oncology novel active substance (NAS) launches (cumulative) 132 (2020–2024). 0 200 400 600 800 2005 2008 2011 2014 2017 2020 2023 403 132 Multi-country oncology trial starts Oncology novel active substance (NAS) launches (cumulative)
View the underlying data
Multi-country oncology trial starts and Oncology novel active substance (NAS) launches (cumulative): Global
Indicator Period Type Value
Multi-country oncology trial starts 2024 Actual 403
Multi-country oncology trial starts 2021 Actual 644
Multi-country oncology trial starts 2015 Actual 503
Oncology novel active substance (NAS) launches (cumulative) 2020–2024 Actual 132
Oncology novel active substance (NAS) launches (cumulative) 2015–2019 Actual 79
Oncology novel active substance (NAS) launches (cumulative) 2005–2024 Actual 282

Shared periods

Side by side

Only one period is published for both series. Comparing anything else would mean comparing different years.

Period Multi-country oncology trial starts Oncology novel active substance (NAS) launches (cumulative)
2015 503 79

Provenance

Where these numbers come from

Multi-country oncology trial starts

Absolute number of multi-country oncology trial starts in a given year.

3 observations in Global · source organisations: IQVIA

Oncology novel active substance (NAS) launches (cumulative)

Total number of oncology novel active substances launched over a stated multi-year period.

3 observations in Global · source organisations: IQVIA

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related